NSCLC patients with activating epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion and exon 21 point mutation (L858R), respond significantly better to first- and second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) than to platinum-based chemotherapy [1,2]. Here, EGFR is linked to non-small cell lung carcinoma.